– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD…
Q4 Revenues of $28.2 millionQ4 Gross Margin of 58.0% (230 bps year-over-year improvement)Q4 operating income of $0.3 million, adjusted operating…
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of…
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG)…
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic…
Up to $3.5 M in cash proceedsUp to $4.5 M in debts conversion Proceeds to be used to further expand…
Solidifying Its Position as a Leading Medical Tourism Hub Newsweek World's Best Hospital 2024 (Malaysia) Newsweek World's Best Hospital 2024…
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean…
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan® topline clinical trial results demonstrate protective efficacy with single…